Cleveland Biolabs (CBLI) Commences Dosing in CBLB612 Phase 2
Tweet Send to a Friend
Cleveland BioLabs, Inc. (NASDAQ: CBLI) announced the start of dosing in a Phase 2, randomized, placebo-controlled clinical study of CBLB612 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
